Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.62 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.62 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL873029 | 0.88 | LMNA (0.56) | GLRA1SLC6A9OR51E2LMNAABCC4 | |
| Oxalic Acid SCHEMBL27336755 | 0.80 | KDM4E (0.42) | GLRA1SLC6A9OR51E2LMNAABCC4 | |
| Benzene SCHEMBL7131871 | 0.79 | GLRA1 (0.83) | GLRA1SLC6A9OR51E2LMNATSHR | |
| Glycine SCHEMBL93765 | 0.79 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2LMNATSHR | |
| Glycine SCHEMBL391786 | 0.79 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2LMNATSHR | |
| Glycine SCHEMBL2116443 | 0.79 | — | — | |
| Glycine SCHEMBL6675874 | 0.79 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2LMNATSHR | |
| Glycine SCHEMBL3640989 | 0.79 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2LMNATSHR | |
| Glycine SCHEMBL391027 | 0.79 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2LMNATSHR | |
| Glycine SCHEMBL6163 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116948159-A | Siloxane supercritical carbon dioxide thickener and preparation method thereof | 西南石油大学 | 2023-10-27 | — | — | CN | claimed |
| CN-114008210-A | Peptide-based non-protein cargo delivery | 费尔丹生物公司 | 2022-02-01 | — | — | CN | claimed |
| CN-111048976-A | Inorganic perovskite quantum dot distributed feedback laser | 曲阜师范大学 | 2020-04-21 | — | — | CN | claimed |
| CN-110994344-A | Organic laser based on holographic polymer dispersed liquid crystal grating | 曲阜师范大学 | 2020-04-10 | — | — | CN | claimed |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| CN-117897401-A | Platform host vs IGF - Adaptation of the culture medium | 美国安进公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| CN-117106085-A | Methods of treating or ameliorating metabolic disorders using combinations of GIPR binding proteins and GLP-1 agonists | 美国安进公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116964069-A | Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof | 纽罗德姆有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116948159-A | Siloxane supercritical carbon dioxide thickener and preparation method thereof | 西南石油大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-110621695-B | anti-JAGGED 1 antigen binding proteins | 安进公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-1545613-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | Seattle Genetics, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050113308-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS, INC. | 2005-05-26 | — | — | US | disclosed |
| US-6884869-B2 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20050009751-A1 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | SEATTLE GENETICS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040157782-A1 | Pentapeptide compounds and uses related thereto | SEAGEN INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1390393-A2 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | Seattle Genetics, Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004010957-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2002088172-A2 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | SEATTLE GENETICS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113308-A1 | Pentapeptide compounds and uses related thereto | VIP, NGLY1, DNPEP | GLRA1 3946/4885SLC6A9 4217/4885OR51E2 839/4885 |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | GLRA1 1598/4885SLC6A9 86/4885OR51E2 1902/4885 |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | COMT, TH, DDT | GLRA1 1903/4885SLC6A9 265/4885OR51E2 2938/4885 |
| US-20050009751-A1 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | VIP, NGLY1, DNPEP | GLRA1 3946/4885SLC6A9 4217/4885OR51E2 839/4885 |
| US-20040157782-A1 | Pentapeptide compounds and uses related thereto | VIP, NGLY1, DNPEP | GLRA1 3946/4885SLC6A9 4217/4885OR51E2 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.